XOlactaThe power and potential of XOlacta
XOlacta contains revolutionary, proprietary drugs, using milk-derived exosomes as a novel drug delivery platform — able to signal, target and offload vital therapies to the exact site where they’re needed most.
HOW IT WORKSXOlacta
1. Loading
Our uniquely isolated milk-derived exosomes are loaded with our ⍺ct-11 peptide to create a powerful new drug, XOlacta.
2. Homing
When orally administered prophylactically, or even 24 hours following injury, XOlacta is taken up by the cells of injured tissue where it's needed most.
3. Offloading
The ⍺ct-11 peptides are released into cells, arresting the bystander effect to prevent the cascade of cell death and scar formation.
APPLICATIONSLife-changing benefits for patients
We’re currently investigating the use of XOlacta as an orally-administered cardio protectant and whole-body protection for both prophylactic and post-exposure use against lethal, therapeutic and background radiation.
CARDIO PROTECTANTReducing fibrosis (scarring) post myocardial infarction
PROACTIVE RADIATION PROTECTANTProtection from high levels of background radiation
“Milk exosomes contain the potential to stand as a new modality of drug delivery — with an all-natural packaging system, Tiny Cargo is poised to revolutionize peptide therapeutics”
Spencer Marsh
Chief Scientific Officer
The Tiny Cargo Company
MEDICAL COUNTERMEASURETreating exposure to high doses of ionizing radiation
We live in a nuclear world, yet currently there are zero treatments for exposures to high doses of ionizing radiation — we aim to change that.
FDA Regulatory Approval — Phase 1, approval expected Q2 2027.
Fast and Effective
Pre-clinical studies show an increase in survival rates of 40% - 70% from 1 dose of XOlacta, when given before or up to 24 hours following exposure.
24hrs
Window
↑ 40%+
Survival rates
FULL BODY RADIOPROTECTANTProtecting healthy cells during radiation exposure
The side effects of radiation exposure during cancer treatment can be devastating, yet there is currently no systemically effective treatment for tissue injury sustained during radiotherapy.
XOlacta is being developed as the first whole-body radioprotectant therapy with potentially life-changing impacts for cancer patients around the world.
FDA Regulatory Approval — Preclinical research, approval expected Q2 2028.
CARDIO PROTECTANT Reducing cardiac injury following myocardial infarction
A heart attack triggers a cascade of cell death and scar tissue formation — and currently, no oral therapy exists to interrupt it. XOlacta aims to change that.
Injured cardiac tissue preferentially takes up orally-administered milk exosomes. Loaded with our αCT11 peptide, XOlacta delivers targeted cardioprotection directly to the site of injury — effective even when administered after the event.
Pre-clinical studies demonstrate efficacy whether XOlacta is administered before or after cardiac ischemia-reperfusion injury.
↓ 61%+
Reduction in cardiac scarring
↑ Ejection fraction
Significant improvement in left ventricular function
RESOURCESLatest publications
